Method for treating a pulmonary hypertension condition

Abstract

A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.

1 .- 58 . (canceled) 
   
   
       59 . A method for treating a pulmonary hypertension condition classified in WHO Group 3 in a subject, comprising administering a therapeutically effective amount of ambrisentan to the subject, wherein the pulmonary hypertension condition is associated with interstitial lung disease (ILD). 
   
   
       60 . The method of  claim 59 , wherein exercise capacity is increased as measured by an increase of at least about 10 m in 6-minute walking distance (6MWD). 
   
   
       61 . The method of  claim 59 , wherein exercise capacity is increased as measured by an increase of at least about 20 m in 6MWD. 
   
   
       62 . The method of  claim 59 , wherein BDI is lowered by at least about 0.5 index point versus baseline. 
   
   
       63 . The method of  claim 59 , wherein BDI is lowered by at least about 1 index point versus baseline. 
   
   
       64 . The method of  claim 59 , wherein the ambrisentan is administered orally once a day. 
   
   
       65 . The method of  claim 64 , wherein the ambrisentan is administered in a daily dosage amount of about 1 mg to about 25 mg. 
   
   
       66 . The method of  claim 64 , wherein the ambrisentan is administered in a daily dosage amount of about 2.5 mg to about 10 mg. 
   
   
       67 . The method of  claim 59 , wherein the ambrisentan is administered for a treatment period of at least about one month. 
   
   
       68 . The method of  claim 67 , wherein the treatment period is at least about three months. 
   
   
       69 . The method of  claim 59 , wherein the ambrisentan is administered in combination therapy with a second active agent which is effective for treatment of the pulmonary hypertension condition or a condition related thereto. 
   
   
       70 . The method of  claim 69 , wherein the second active agent comprises at least one drug selected from the group consisting of prostanoids, phosphodiesterase-5 (PDE5) inhibitors, endothelin receptor antagonists (ERAs) other than ambrisentan, calcium channel blockers, diuretics, anticoagulants, oxygen and combinations thereof. 
   
   
       71 . The method of  claim 70 , wherein the second agent comprises at least one diuretic selected from the group consisting of chlormerodrin, chlorothiazide, chlorthalidone, meralluride, mercaptomerin sodium, mercumatilin sodium, mercurous chloride, mersalyl, pamabrom, protheobromine, theobromine, canrenone, oleandrin, spironolactone, acetazolamide, ambuside, azosemide, bumetanide, butazolamide, chloraminophenamide, clofenamide, clopamide, clorexolone, disulfamide, ethoxzolamide, furosemide, mefruside, methazolamide, piretanide, torsemide, trip amide, xip amide, althiazide, bendroflumethiazide, benzthiazide, benzylhydrochlorothiazide, buthiazide, chlorthalidone, cyclopenthiazide, cyclothiazide, ethiazide, fenquizone, hydrochlorothiazide, hydroflumethiazide, indapamide, methyclothiazide, metolazone, paraflutizide, polythiazide, quinethazone, teclothiazide, trichlormethiazide, aminometradine, amiloride, Biogen BG 9719, chlorazanil, ethacrynic acid, etozolin, isosorbide, Kiowa Hakko KW 3902, mannitol, muzolimine, perhexyline, Sanofi-Aventis SR 121463, ticrynafen, triamterene, and urea.